Iovance director Wendy Yarno to retire in 2026

Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company’s annual meeting of stockholders, which is anticipated to be held in June 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company’s annual meeting of stockholders, which is anticipated to be held in June 2026.

Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

What board change did Iovance Biotherapeutics (IOVA) disclose in this 8-K?

Iovance Biotherapeutics disclosed that board member Wendy Yarno will retire and not stand for re-election at the upcoming annual meeting. She will remain on the Board until that meeting, and the company expressed appreciation for her service and contributions.

When will Iovance Biotherapeutics (IOVA) director Wendy Yarno retire from the Board?

Wendy Yarno will retire from the Iovance Biotherapeutics Board at the company’s annual meeting of stockholders, currently anticipated for June 2026. She will continue serving as a director until that meeting, providing continuity during the transition period for the Board.

Did Wendy Yarno’s retirement from Iovance Biotherapeutics (IOVA) involve any disagreement with the company?

The company stated that Wendy Yarno’s decision to retire and not stand for re-election was not due to any disagreement regarding Iovance’s operations, policies, or practices. This language signals an orderly governance transition rather than a dispute-driven departure.

What role did Wendy Yarno hold at Iovance Biotherapeutics (IOVA) before announcing retirement?

Wendy Yarno served as a member of the Board of Directors of Iovance Biotherapeutics. She notified the Board on March 17, 2026 that she will retire and not stand for re-election at the company’s anticipated June 2026 annual stockholder meeting.

How did Iovance Biotherapeutics (IOVA) characterize Wendy Yarno’s retirement from the Board?

Iovance Biotherapeutics indicated that Wendy Yarno’s retirement is a personal decision, explicitly noting no disagreement over operations, policies, or practices. The company publicly thanked her for her service, framing the change as a normal board succession event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/20/2026 - 05:00 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 17, 2026

IOVANCE BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State of Incorporation)

001-36860		75-3254381
Commission File Number		(I.R.S. Employer Identification No.)

825 Industrial Road, Suite 100
San Carlos, California		94070
(Address of Principal Executive Offices)		(Zip Code)

(650) 260-7120
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.000041666 per share	IOVA	The Nasdaq Stock Market LLC

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the “Board”) of Iovance Biotherapeutics, Inc. (the “Company”), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company’s annual meeting of stockholders (the “Annual Meeting”) currently anticipated to be held in June 2026. Ms. Yarno will serve out her current term as a director of the Company until the Annual Meeting. The decision to retire and not stand for re-election is not due to a disagreement between the Company and Ms. Yarno on any matter regarding the Company’s operations, policies, or practices. The Company thanks Ms. Yarno for her service to the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Iovance Biotherapeutics, Inc.

Dated: March 20, 2026	By:	/s/ Frederick G. Vogt
	Name:	Frederick G. Vogt, Ph.D., J.D.
	Title:	Interim CEO and President, and General Counsel

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents